Date: 2017-05-09
Type of information: Nomination
Compound:
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 9, 2017, Alnylam Pharmaceuticals announced the appointment of several experienced industry leaders to key leadership roles. Manmeet S. Soni joined the company as Chief Financial Officer. In this role Mr. Soni will provide strategic leadership in the overall financial management of Alnylam, including for the global finance, investor relations and communications teams. He is the former Chief Financial Officer and Treasurer of Ariad Pharmaceuticals, where he played a central role in the strategic review, turnaround and subsequent acquisition of Ariad by Takeda Pharmaceuticals. Before joining Ariad , he worked at Pharmacyclics where he served most recently as Chief Financial Officer and Treasurer. Mr. Soni also played a vital role in the acquisition of Pharmacyclics by Abbvie for $21 billion .
Theresa Heggie , Senior Vice President, Head of Europe and Canada will be responsible for the strategic direction and activity of all of Alnylam's operations in Europe and Canada including building the go-to-market strategy across multiple products and therapeutic areas. Most recently she served as the Chief Marketing and Strategy Officer at The British United Provident Association ( Bupa ). Previously, Ms. Heggie held various senior commercial positions at Shire Human Genetic Therapies (and formerly TKT) including the roles of Vice President and General Manager of EMEA, Chief Executive Officer of Jerini AG (a Shire acquisition), and Senior Vice President of Global Commercial Operations. Earlier, at Baxter Healthcare she held numerous roles including Vice President of Global Marketing. Early in her career, Ms. Heggie held a variety of sales and marketing positions at Janssen Pharmaceuticals . She formerly served as a member of the board of directors of Swedish Orphan Biovitrum AB. Theresa received a BSc from Cornell University .
Ms. Heggie will report to Barry Greene , President and will be based at Alnylam's European headquarters in Zug, Switzerland .
Peter Smith , Ph.D., Senior Vice President, Early Development will be responsible for all aspects of non-clinical safety, drug metabolism and pharmacokinetics, bioanalysis and biomarker programs, providing both scientific and drug development leadership. Dr. Smith brings more than 30 years of pharma industry experience to Alnylam, most recently joining from Moderna , where he was Head of R&D Non-Clinical. He joined Moderna from Millennium Pharmaceuticals , where he most recently served as co-head of R&D and a member of the company's management team. In this role, he was responsible for management of all Non-Clinical groups and Pharmaceutical Sciences. His extensive experience in drug discovery and development spans multiple therapeutic areas and therapeutic modalities. Dr. Smith has a B.S. in biology from Fairfield University and a Ph.D. in Pharmacology and Toxicology from the University of Arizona . His postdoctoral fellowship in biochemical toxicology was undertaken at SmithKline. He has published and presented extensively in the pharm/tox area as well as in the area of drug development.
Dr. Smith will report to Akshay Vaishnaw , Executive Vice President of Research and Development.
Alan Eisenberg , Vice President, Global Public Policy and Government Relations, will lead federal, state and local government affairs and public policy initiatives globally. Alan joins Alnylam from Celgene where he was the Vice President for Federal Government Relations. In this role, he led Celgene's Federal Government Relations function and had direct responsibility for the Company's public policy engagement with Congress , relevant Executive Branch agencies and other Washington, D.C. based stakeholders. Prior to Celgene, Mr. Eisenberg was Executive Vice President for Emerging Companies & Business Development at the Biotechnology Innovation Organization (BIO), leading BIO's services and advocacy efforts for BIO's pre-market and early stage commercial companies, in addition to serving in other senior leadership roles at BIO.
Previously, Mr. Eisenberg served as Health and Economics Policy Advisor to Congressman Jim Greenwood and prior to that, he served on the staff of the Senate HELP Public Health Subcommittee , and also was a legislative assistant for Congressman John Shadegg . Earlier in his career he spent four years with Ford Motor Company.
Mr. Eisenberg holds a Master in Public Policy degree from Harvard University , a Master of Science in Finance degree from George Washington University , and a Bachelor of Science degree from Union College .
Mr. Eisenberg will report to Laurie Keating , Senior Vice President and General Counsel.
Financial terms:
Latest news:
Is general: Yes
